This article has Open Peer Review reports available.
Effects of Allium victorialis leaf extracts and its single compounds on aldose reductase, advanced glycation end products and TGF-β1 expression in mesangial cells
© Kim et al.; licensee BioMed Central Ltd. 2013
Received: 2 July 2013
Accepted: 26 September 2013
Published: 3 October 2013
Accumulating evidences suggest that aldose reductase (AR) inhibitors and advanced glycation end product (AGE) formation inhibitors may prevent chronic hyperglycemia-induced long-term complication in diabetes. Transforming growth factor-beta1 (TGF-β1) plays an important role in the development of diabetic nephropathy. Allium species have been utilized in folk medicine throughout the world for the treatment of various physical disorders. However, the benefits of Allium victorialis (A. victorialis) against diabetic complications, especially nephropathy, have yet to be explored. In the present study, we investigated the protective effect of the compounds isolated from A. victorialis leaf on diabetic nephropathy.
In vitro AR activity, AGEs formation, and AGE-receptor for AGEs (RAGE) binding in human RAGE (hRAGE)-overexpressing cells were tested. High glucose-induced transforming growth factor-beta1 (TGF-β1) expression was also examined in mouse kidney mesangial cells (MMCs) cultured under high glucose.
Of the isolated eight compounds from A. victorialis leaf extracts tested, quercitrin exhibited the most pronounced inhibitory effects on AR activity (IC50 value of 0.17 μM) and AGEs formation (IC50 value of 4.20 μM). Furthermore, quercitrin disrupted AGE-RAGE binding in a concentration-dependent manner in hRAGE-overexpressing cells. Additionally, of the eight compounds tested, ferulic acid significantly reduced high glucose-induced TGF-β1 expression and secretion in MMCs.
Our results suggest that active compounds isolated from A. victorialis leaf exhibit inhibitory effects on AR activity in rat lenses and AGE formation. Further, ferulic acid reduces TGF-β1 mRNA expression and secretion in MMCs under diabetic conditions. Thus, A. victorialis is a good candidate for the development of treatments for diabetic nephropathy.
Chronic hyperglycemia is the most common feature of all forms of diabetes mellitus, and it accelerates the induction of aldose reductase (AR, EC 184.108.40.206) and the irreversible formation of advanced glycation end products (AGEs), which play important roles in the pathogenesis of diabetic complications . Diabetic nephropathy is a major complication of diabetes mellitus, and although the mechanism of glomerulosclerosis still remains unclear, the irreversible formation of AGEs, polyol accumulation, and oxidative stress have been considered the major causes of diabetic nephropathy . AR, the first rate-limiting enzyme in the polyol pathway, is present in the eyes, kidneys, and other tissues affected by diabetic complications. Increased glucose enters the polyol pathway, where it is reduced by AR to sorbitol [2, 3]. AR inhibitors (ARIs), such as epalrestat, 3,3-tetramethyleneglutaric acid (TMG), and fidarestat, have been developed, and some have been revealed to prevent diabetic nephropathy in animal models or patients [3–7]. ARIs from natural products have been found to prevent or delay the development of diabetic complications in animal models [8–10].
Transforming growth factor-beta 1 (TGF-β1) is a multifunctional cytokine that plays important roles in cell proliferation, wound healing, differentiation, apoptosis, and the immune response in several cells . In particular, TGF-β1 is a key mediator of diabetic nephropathy that increases the levels of extracellular matrix (ECM) proteins, such as collagen I and IV, laminin, and fibronectin, in the glomeruli . In addition, TGF-β has been identified as a critical regulator and mediator of pathophysiological processes of ocular tissue development or repair. TGF-β–mediated signaling is involved in the progression of diabetic nephropathy, and high levels of TGF-β are found in diabetic kidneys.
Natural products and their active constituents have been reportedly used for the treatment of diabetes and diabetic complications . The genus Allium comprises more than 600 different species distributed throughout North America, North Africa, Europe, and Asia. Many Allium species have been utilized in folk medicine throughout the world for the treatment of various physical disorders such as burns, wounds, headaches, chest colds, and rheumatism . Allium victorialis var. platyphyllum (Liliaceae), one of the most popular Allium species, is an edible perennial herb widely distributed on Ulleung Island and Mt. Hambeak of the Korean Peninsula. Recently, Allium victorialis (A. victorialis) has received much attention owing to its diverse and potentially significant pharmacological properties including antiarteriosclerotic, anticancer, antioxidant, antidiabetic, antiobesity, antineuroinflammatory, hepatoprotective, and nephroprotective effects [12–21].
In this paper, we examined the effects of eight compounds (1–8) isolated from A. victorialis leaf on AR activity, AGE formation, and TGF-β1 mRNA expression and protein secretion in mouse glomerular mesangial cells (MMCs) cultured under diabetic conditions. Furthermore, binding between AGE and receptor for AGE (RAGE) in human RAGE (hRAGE)-overexpressing MMCs was analyzed, and the most active compound was identified. These results show that single compounds from A. victorialis leaf extracts have preventive effects against diabetic nephropathy and may be useful as candidates for preclinical study in the treatment of diabetic nephropathy.
Plant materials and chemicals
The leaf of A. victorialis were purchased from a commercial supplier in Goryung, (Gyeongbuk, Korea, in January, 2005) and identified by Prof. K-R Park in the Department of Herbology, The Medical Research center for Globalization of Herbal Formulation, Daegu Haany University. A herbarium voucher specimen (no. KIOM-ALVI) has been deposited at the Herbarium of the Diabetic Complications Research Group, Korea Institute of Oriental Medicine. Antibodies were purchased from Cell Signaling (Beverly, MA) and Santa Cruz Biotechnology (Santa Cruz, CA). All other reagents were obtained from Sigma-Aldrich (St. Louis, MO). Reagents used for cell culture were purchased from GIBCO-BRL (Grand Island, NY).
General experimental procedures
Optical rotations were measured on a JASCO P-2000 digital polarimeter. Hydrogen 1 (300 MHz) and carbon 13 nuclear magnetic resonance (NMR; 75 MHz) spectra were obtained using a Bruker DRX-300 spectrometer with tetramethylsilane as an internal standard. Two-dimensional-NMR experiments (correlation spectroscopy, heteronuclear multiple-quantum correlation, and heteronulear multiple bond correlation) were run on a Bruker Avance 500 NMR spectrometer. Electrospray ionization mass spectrometry spectra were recorded on a Shimadzu liquid chromatography-mass spectrometry-ion trap-time of flight spectrometer. Column chromatography was performed using silica gel (70–230 mesh, Merck), YMC-gel ODS-A (12 nm, S-75 μm, YMC), and Sephadex LH-20 (Amersham Pharmacia Biotech). Thin-layer chromatography was performed on pre-coated silica gel 60 F254 (0.25 mm, Merck) and RP-18 F254s plates (0.25 mm, Merck). Spots were detected by utraviolet light (254 nm) and spraying with 10% H2SO4 followed by heating.
Extraction and isolation
Inhibitory effect of extracts, fractions, and compounds isolated from A. victorialis on AR and AGEs formation
Extracts, fractions, and isolated compounds
A. victorialis 50% EtOH
A. victorialis EtOAc
A. victorialis BuOH
5.07±0.06 μM (0.94±0.01 μg/ml)
1.03±0.07 mM (76.47±4.81 μg/ml)
Rat lens AR activity
AR activity was measured as described previously [9, 22]. All animal procedures were approved by the Korea Institute of Oriental Medicine Institutional Animal Care Committee on animal care at our institute and conducted according to institutional guidelines. Rat lenses were isolated from the eyes of 8-week-old Sprague–Dawley rats (Orient Co., Seongnam, Korea) and homogenized in 12 volumes of 150 mM sodium phosphate buffer (pH 6.2) and 10 mM 2-mercaptoethanol. The homogenate was centrifuged at 14,000 rpm for 30 min, and the supernatant was used as crude rat lens AR. The incubation mixture contained 150 mM sodium phosphate buffer, 0.15 mM nicotinamide adenine dinucleotide phosphate (NADPH), 10 mM dl-glyceraldehyde as a substrate, and 700 μg/ml of enzyme substrate, with or without compounds or positive control, in a total volume of 1.0 ml. The reaction was initiated by the addition of NADPH at 37°C and stopped by the addition of 0.15 ml of 0.5 N HCl. Next, 0.5 ml of 6 M NaOH containing 10 mM imidazole was added, and the solution was heated at 60°C for 15 min to convert NADP to a fluorescent product. The fluorescence (ex. 360 nm/ em. 460 nm) was assayed using a spectrofluorometric detector (Synergy HT, Bio-Tek, Winooski, VT). The concentration of each test sample that inhibited activity by 50% (IC50) was estimated from the least-squares regression line of the logarithmic concentration plotted against the remaining activity.
Determination of AGEs formation
AGEs formation assay was performed as previously described [23, 24]. Bovine serum albumin (BSA, 10 mg/ml, Sigma-Aldrich) in 50mM phosphate buffer (pH 7.4) with containing 0.02% sodium azide to prevent bacterial growth was added to 0.2 M fructose and glucose. The reaction mixture was then mixed with compounds or aminoguanidine (AG, Sigma-Aldrich). After incubating at 37°C for 7 days, the fluorescent reaction products were assayed on a spectrofluorometric detector (BIO-TEK, Synergy HT, Ex: 350 nm/Em: 450 nm). AGEs assay was performed in quadruplicate. The concentration of each test sample giving 50% inhibition of the activities (IC50) was estimated from the least-squares regression line of the logarithmic concentration plotted against the remaining activity.
Mouse kidney mesangial cells (SV40 MES13, MMC) were obtained from the American Type Culture Collection (#CRL-1927, Rockville, MD) and cultured in Dulbecco's modified Eagle's medium:F-12 (3:1) supplemented with 14 mM HEPES, penicillin 100 U/ml, streptomycin 100 μg/ml, and 5% fetal bovine serum. Cells were routinely grown to confluence in a humidified 37°C, 5% CO2 incubator.
RNA extraction and semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis
Total cellular RNA was extracted with TRIzol (Invitrogen, Carlsbad, CA), quantified by measuring the absorbance at 260 nm, and stored at -80°C until analysis. The expression of TGF-β1 and GAPDH mRNAs was detected by RT-PCR analysis. The extracted RNA (1 μg) was subjected to a reverse transcriptase reaction with the Maxime RT premix (Intron, Daejeon, Korea) at 42°C for 60 min and 72°C for 10 min. Subsequently, semi-quantitative PCR was performed with Accupower® PCR premix (Intron, Daejeon, Korea). The primer sequences were as follows: mouse TGF-β1 (sense) 5’- TGA ACC AAG GAG ACG GAA TAC AGG -3’, (anti-sense) 5'- GCC ATG AGG AGC AGG AAG GG -3’ and mouse GAPDH (sense) 5’- ACG GCA AAT TCA ACG GCA CAG -3’, (anti-sense) 5’- AGA CTC CAC GAC ATA CTC AGC AC -3’. Aliquots of PCR products were electrophoresed on 1.2% agarose gels and visualized after ethidium bromide staining.
Determination of secreted TGF-β1 expression in MMCs using enzyme-linked immunosorbent assay (ELISA)
The levels of TGF-β1 in the medium were determined as described previously . The medium was replaced with serum-free medium containing compound under high glucose conditions for 24 h. This medium was then harvested and TGF-β1 was activated by treatment with 1 N HCl (0.1 ml/0.5 ml of conditioned media) for 10 min at room temperature, then 0.1 ml 1.2 N NaOH/0.5 M HEPES was added. Quantikine mouse TGF-β1 ELISA (R&D systems, Minneapolis, MN) was performed according to the manufacturer’s protocol, and the TGF-β1 levels were normalized to those of total protein. Medium without cells that had been incubated under the same conditions was used as a control for the ELISA.
Detection of live cell-based AGE-BSA/RAGE binding
AGE-BSA/RAGE binding in the cells was determined as described previously . Briefly, Alexa 488 labeling of AGE-BSA was performed using the Alexa Fluor® 488 protein labeling kit (Molecular Probes, Eugene, OR). For the binding assay, human RAGE-overexpressing cells (1×104) were seeded onto a 96-well assay plate with a clear bottom lid and black plate (Corning, NY) and incubated with serum-free media for 24 h. Before binding, 3% BSA was added for 30 min to block non-specific binding. Cells were treated with 5 μg of Alexa Fluor 488-labeled AGE-BSA in a total volume of 100 μl serum-free medium and incubated in the dark for 6 h in a 5% CO2 humidified atmosphere at 37°C. Compounds were added after the addition of AGE-BSA-Alexa Fluor 488 to hRAGE-overexpressing cells. The non-specific binding of AGE-BSA-Alexa Fluor 488 to cell surface proteins other than hRAGE was compared by incubating cells with untreated cells (blank). After binding, 100 μl Opti-MEM were added to the washed plates, and the plates were then analyzed using a microtiter plate reader (Bio-Tek, Winooski, VT) with excitation and emission wavelengths of 485 and 528 nm, respectively.
Data are expressed as mean ± S.E.M. of multiple experiments. Paired Student's t-tests were used to compare two groups, or analysis of variance with Tukey’s was used for multiple comparison tests using PRISM software (Graph Pad, San Diego, CA). Values of p < 0.05 were considered statistically significant.
Results and discussion
Structure elucidation of compounds
Rat lens AR activity, AGE formation, and AGE/RAGE-binding in hRAGE-overexpressing cells
Inhibition of high glucose-induced TGF-β1 expression and secretion in MMCs
In summary, our data suggest that active compounds isolated from A. victorialis leaf exhibit inhibitory effects on AR activity and AGE formation. Further, ferulic acid reduces TGF-β1 mRNA expression and secretion in MMCs under diabetic conditions. Thus, the compounds isolated from A. victorialis leaf provide some scientific evidence to support the folk medicinal utilization of A. victorialis in the treatment of diabetic nephropathy. Furthermore, A. victorialis is a good candidate for the development of treatments for diabetic nephropathy.
This research was supported by grant [K12040] from the Korea Institute of Oriental Medicine (KIOM) and by grant  from the Global Leading Technology Program of the Office of Strategic R&D Planning (OSP) funded by the Ministry of Knowledge Economy, Republic of Korea. The authors would like to thank Prof. Kyu-Ryul Park, PhD; Department of Herbology, The Medical Research center for Globalization of Herbal Formulation, Daegu Haany University for identification of plant.
- Huebschmann AG, Regensteiner JG, Vlassara H, Reusch JE: Diabetes and advanced glycoxidation end products. Diabetes Care. 2006, 29: 1420-1432. 10.2337/dc05-2096.View ArticlePubMedGoogle Scholar
- Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005, 54: 1615-1625. 10.2337/diabetes.54.6.1615.View ArticlePubMedGoogle Scholar
- Hotta N, Toyota T, Matsuoka K, Shigeta Y, Kikkawa R, Kaneko T, Takahashi A, Sugimura K, Koike Y, Ishii J, Sakamoto N: Clinical efficacy of fidarestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double-blind parallel group study. Diabetes Care. 2001, 24: 1776-1782. 10.2337/diacare.24.10.1776.View ArticlePubMedGoogle Scholar
- Kinoshita JH, Dvornik D, Kraml M, Gabbay KH: The effect of an aldose reductase inhibitor on the galactose-exposed rabbit lens. Biochim Biophys Acta. 1968, 158: 472-475. 10.1016/0304-4165(68)90305-X.View ArticlePubMedGoogle Scholar
- Obrosova IG, Minchenko AG, Vasupuram R, White L, Abatan OI, Kumagai AK, Frank RN, Stevens MJ: Aldose reductase inhibitor fidarestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin-diabetic rats. Diabetes. 2003, 52: 864-871. 10.2337/diabetes.52.3.864.View ArticlePubMedGoogle Scholar
- Itagaki I, Shimizu K, Kamanaka Y, Ebata K, Kikkawa R, Haneda M, Shigeta Y: The effect of an aldose reductase inhibitor (Epalrestat) on diabetic nephropathy in rats. Diabetes Res Clin Pract. 1994, 25: 147-154. 10.1016/0168-8227(94)90002-7.View ArticlePubMedGoogle Scholar
- Sung JK, Koh JH, Lee MY, Kim BH, Nam SM, Kim JH, Yoo JH, Kim SH, Hong SW, Lee EY, Choi R, Chung CH: Aldose reductase inhibitor ameliorates renal vascular endothelial growth factor expression in streptozotocin-induced diabetic rats. Yonsei Med J. 2010, 51: 385-391. 10.3349/ymj.2010.51.3.385.View ArticlePubMedPubMed CentralGoogle Scholar
- de la Fuente JA, Manzanaro S: Aldose reductase inhibitors from natural sources. Nat Prod Rep. 2003, 20: 243-251. 10.1039/b204709h.View ArticlePubMedGoogle Scholar
- Kim YS, Kim NH, Jung DH, Jang DS, Lee YM, Kim JM, Kim JS: Genistein inhibits aldose reductase activity and high glucose-induced TGF-beta2 expression in human lens epithelial cells. Eur J Pharmacol. 2008, 594: 18-25. 10.1016/j.ejphar.2008.07.033.View ArticlePubMedGoogle Scholar
- Marles RJ, Farnsworth NR: Antidiabetic plants and their active constituents,". Phytomedicine. 1995, 2: 137-189. 10.1016/S0944-7113(11)80059-0.View ArticlePubMedGoogle Scholar
- Roberts AB, McCune BK, Sporn MB: TGF-beta: regulation of extracellular matrix. Kidney Int. 1992, 41: 557-559. 10.1038/ki.1992.81.View ArticlePubMedGoogle Scholar
- Block E: Food Phytochemicals for Cancer Prevention I. 1994, Washington, DC: American Chemical Society, 84-96. Flavorants from garlic, onion, and other Alliums and their cancer-preventive properties in food phytochemicals for cancer prevention , ACS Symposium Series, 546Google Scholar
- Lee KT, Choi JH, Kim DH, Son KH, Kim WB, Kwon SH, Park HJ: Constituents and the antitumor principle of Allium victorialis var. platyphyllum. Arch Pharm Res. 2001, 24: 44-50. 10.1007/BF02976492.View ArticlePubMedGoogle Scholar
- Shirataki Y, Motohashi N, Tani S, Sunaga K, Sakagami H, Satoh K, Nakashima H, Kanamoto T, Wolfard K: Antioxidative activity of Allium victorialis L. extracts ",". Anticancer Res. 2001, 21: 3331-3339.PubMedGoogle Scholar
- Kim TG, Kim SH, Kang SY, Jung KK, Choi DH, Park YB, Ryu JH, Han HM: Antiatherogenic effect of the extract of Allium victorialis on the experimental atherosclerosis in the rabbit and transgenic mouse,". Kor. J. Pharmacogn. 2000, 31: 149-156.Google Scholar
- Lee KT, Choi JH, Kim DH, Son KH, Kim WB, Kwon SH, Park HJ: Constituents and the antitumor principle of Allim victorials var. platyphyllum. Arch Pharm Res vol. 2001, 24: 44-50. 10.1007/BF02976492.View ArticleGoogle Scholar
- Woo KW, Moon E, Park SY, Kim SY, Lee SY: Flavonoid glycosides from the leaves of Allium victorialis var. platyphyllum and their anti-neuroinflammatory effects. Bioorg Med Chem Lett. 2012, 22: 7465-7470. 10.1016/j.bmcl.2012.10.043.View ArticlePubMedGoogle Scholar
- Ahn YM, Lim SJ, Han HK, Choi SS: Effects of Allim vegetable intake on levels of plasma glucose, lipid and minerals in streptozotocin induced diabetic rat. Korean J Nutrition. 2006, 39: 433-443.Google Scholar
- Ku SK, Chung IK, Chen WH, Kim J-W: Allium victorials Leaf Extract Prevents High Fat Diet Induced Obesity in Mice. J Vet Clin vol. 2011, 28: 280-286.Google Scholar
- Choi JW, Lee KT, Kim WB: Phamacological effects of the Allim victorials var. platyphyllum extracts on the rats induced by streptozotocin, poloxamer-407, CCl4 and D-galactosamine. Kor J Pharmacogn. 2003, 34: 250-255.Google Scholar
- Ku SK, Kim JW: Hepatoprotective and nephroprotective effects of Allim victorials leaf extracts on the high fat diet supplied mice. J Vet Clin. 2010, 27: 225-231.Google Scholar
- Dufrane SP, Malaisse WJ, Sener A: A micromethod for the assay of aldose reductase, its application to pancreatic islets. Biochem Med. 1984, 32: 99-105. 10.1016/0006-2944(84)90012-7.View ArticlePubMedGoogle Scholar
- Jung DH, Kim YS, Kim JS: Screening system of blocking agents of the receptor for advanced glycation endproducts in cells using fluorescence. Biol Pharm Bull. 2012, 35: 1826-1830. 10.1248/bpb.b12-00361.View ArticlePubMedGoogle Scholar
- Jang DS, Lee GY, Lee YM, Kim YS, Sun H, Kim DH, Kim JS: Flavan-3-ols having a gamma-lactam from the roots of Actinidia arguta inhibit the formation of advanced glycation end products in vitro. Chem Pharm Bull (Tokyo). 2009, 57: 397-400. 10.1248/cpb.57.397.View ArticleGoogle Scholar
- Kim YS, Kim NH, Yoo NH, Lee YM, Jeong IH, Kim JS: Quercitrin gallate inhibits aldose reductase activity and xylose-induced lens opacity and oxidation. Biomed & Aging Path. 2011, 1: 123-127. 10.1016/j.biomag.2011.06.007.View ArticleGoogle Scholar
- Wieslawa B, Irena M: Flavonoids from Aquilegia vulgaris L. flowers. Acta Pol Pharm Drug Res. 1999, 56: 241-244.Google Scholar
- Michael HN, Shafik RE, Rasmy GE: Studies on the chemical constituents of fresh leaf of Eruca sativa extract and its biological activity as anticancer agent in vitro. J Med Plants Res. 2011, 5: 1184-1191.Google Scholar
- Mok SY, Lee S: Identification of flavonoids and flavonoid rhamnosides from Rhododendron mucronulatum for. albiflorum and their inhibitory activities against aldose reductase. Food Chem. 2013, 136: 969-974. 10.1016/j.foodchem.2012.08.091.View ArticlePubMedGoogle Scholar
- Agrawal PK: Carbone-13 NMR of flavonoids. 1989, New York: ElsevierGoogle Scholar
- Ma SJ, Kuk JH, Ko B: Isolation and characterization of 4-hydroxycinnamic acid with antimicrobial activity from Aralia elata. Agri Chem Biotech. 1996, 39: 265-267.Google Scholar
- Lee HJ, Lee SK, Choi DH: Extractives from the Allium victorials. J Korean For Soc vol. 2007, 96: 620-624.Google Scholar
- Jung HA, Moon HE, Oh SH, Kim BW, Sohn HS, Choi JS: Kinetics and molecular docking studies of kaempferol and its prenylated derivatives as aldose reductase inhibitors. Chem Biol Interact. 2012, 197: 110-118. 10.1016/j.cbi.2012.04.004.View ArticlePubMedGoogle Scholar
- Lamson DW, Brignall MS: Antioxidants and cancer, part 3: quercetin. Altern Med Rev. 2000, 5: 196-208.PubMedGoogle Scholar
- Comalada M, Camuesco D, Sierra S, Ballester I, Xaus J, Gálvez J, Zarzuelo A: In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur J Immunol. 2005, 35: 584-592. 10.1002/eji.200425778.View ArticlePubMedGoogle Scholar
- Jung DH, Kim YS, Kim JS: KIOM-79 prevents S100b-induced TGF-beta1 and fibronectin expression in mouse mesangial cells. J Ethnopharmacol vol. 2009, 125: 374-379. 10.1016/j.jep.2009.08.002.View ArticleGoogle Scholar
- Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN: Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol. 2000, 278: F628-F634.PubMedGoogle Scholar
- Sharma K, Ziyadeh FN: Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes. 1995, 44: 139-1146. 10.2337/diab.44.2.139.View ArticleGoogle Scholar
- Choi R, Kim BH, Naowaboot J, Lee MY, Hyun MR, Cho EJ, Lee ES, Lee EY, Yang YC, Chung CH: Effects of ferulic acid on diabetic nephropathy in a rat model of type 2 diabetes. Exp Mol Med. 2011, 43: 676-683. 10.3858/emm.2011.43.12.078.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/13/251/prepub
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.